Diverse base supports solid growth in 2022 for STADA Arzneimittel

6 March 2023
stada-location-big

German generics drugmaker STADA Arzneimittel  (SAZ: Xetra) has reported 11% growth in sales in its annual 2022 results statement, propelled by “numerous launches and line extensions, market-share gains and strong supply reliability.”

The firm’s consumer healthcare and specialty drug businesses were key growth drivers in 2022, with revenues reaching 3.8 billion euros ($4 billion) overall.

The earnings before interest, tax, depreciation and amortization (EBITDA) figure improved by 17%, reaching 875 million euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics